Latest Conference Articles

Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Real-World Findings Emphasize the Need for Early Genetic Testing in HRR-Mutated mCRPC

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Long-Term ADT Plus High-Dose Radiation Provides Survival Advantage in High-Risk Prostate Cancer

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Neoadjuvant Darolutamide/ADT Followed By Radical Prostatectomy Is Safe/Effective in Localized Prostate Cancer

Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.

Abiraterone Acetate/Prednisone/Apalutamide Maintains HRQOL Outcomes in Prostate Cancer

Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.

Atezolizumab Plus Cabozantinib Improves PFS Over Novel Hormonal Therapy in mCRPC

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Underutilization of HRR Mutation Testing in Clinic Signals Unmet Need in mCRPC

Sub-optimal integration of HRR mutation testing into clinical practice leads to a negative impact on treatment selection and outcomes in mCRPC.

Prior EBRT Shows No Correlation With Hematologic Toxicity in Patients With mCRPC Treated With Ra-223

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

Darolutamide Plus Docetaxel/ADT Does Not Increase Hospitalization in mHSPC

Darolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.

Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon Cancer

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

ctDNA Is Predictive of DFS, Offers Prognostic Tool in CRC

Minimal residual disease detection by ctDNA was predictive and prognostic of disease recurrence and response to adjuvant chemotherapy in patients with CRC.

Frontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRC

Nivolumab/ipilimumab reduced the risk of disease progression or death vs chemotherapy in previously untreated patients with metastatic colorectal cancer.

Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

Real-World Data Identify Factors Associated With Long-Term Response to Regorafenib in mCRC

Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.

Dr Ludmir on the Rationale For the EXTEND Trial in PDAC

Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.

Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRC

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

DKN-01 Plus Bevacizumab and Chemotherapy Shows Tolerability, Activity in MSS CRC

DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.

Neoadjuvant Botensilimab/Balstilimab Combo Induces Early Efficacy in pMMR/dMMR CRC

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

Fruquintinib Plus BSC Provides Clinically Meaningful Quality-Adjusted Survival Benefit Vs BSC Alone in mCRC

An improvement in quality-adjusted survival benefit was observed with fruquintinib/BSC vs BSC alone in patients with mCRC enrolled in the FRESCO study.

Larotrectinib Displays Efficacy, Tolerability in TRK Fusion+ Gastrointestinal Cancers

Larotrectinib led to long-lasting responses, encouraging survival, and a favorable safety profile in TRK fusion-positive gastrointestinal cancers.

177Lu-Dotatate Prolongs PFS Vs High-Dose Octreotide in GEP-NETs

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

FOLFOXIRI Plus Bevacizumab Use Rises Over Time in mCRC

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.

Dr Shitara on the 4-Year Outcomes of the CheckMate 649 Trial in GEJ Adenocarcinoma

Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.

Dr Lencioni on the Results of the EMERALD-1 Trial in Unresectable HCC

Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.

Subgroup Analysis Reveals Higher Incidence of Serious TEAEs With Regorafenib in Patients With uHCC and CP-B Liver Function

Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.

Fostrox/Lenvatinib Combination Displays Efficacy, Tolerability in Pretreated HCC

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.